



## Asthma/Respiratory Enrollment Form Medford Chemists

2608 Route 112, Medford, NY 11763 | Email: info@medfordchemists.com | Phone: 1-855-MEDCHEM | Fax: 631-475-4288

PATIENT INFORMATION				
Name:	Date of Birth:		O Male   O Female	
Address:	City:	State:	Zip:	
Phone:	Alt Phone:		Primary Language:	
Emergency Contact, Phone:	Pt Email:		SSN:	
PRESCRIBER INFORMATION				
Prescribing Practitioner:			NPI#:	
Supervising Physician:			NPI#:	
Address:	City:	State:	Zip:	Tax ID:
Phone:	Office Contact:		Fax:	
MEDICAL INFORMATION				
<b>** PLEASE FAX COPY OF PRESCRIPTION &amp; MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY **</b>				
ICD-10 Code & Description: _____				
Patient Evaluation: Height: _____ in/cm   Weight: _____ kg/lbs				
Allergies: _____				
Eosinophils: _____   Date assessed: _____				
Steroid Dependent: <input type="checkbox"/> Yes <input type="checkbox"/> No				
Needs by Date: _____   Ship to : <input type="checkbox"/> Patient <input type="checkbox"/> Office <input type="checkbox"/> Other (include address): _____				
PRESCRIPTION INFORMATION				
Drug	Dose	Directions	Qty/Day Supply	Refills
<input type="checkbox"/> Dupixent (dupilumab)	<input type="checkbox"/> 200mg/1.14mL PFS  <input type="checkbox"/> 300mg/2mL PFS  (COMES 2/BOX)	<b>Initial dose:</b> <input type="checkbox"/> Inject 2 doses subcutaneously (different injection sites) initially then 1 dose subcutaneously every other week  <b>Maintenance dose:</b> <input type="checkbox"/> Inject 1 dose subcutaneously every other week	Qty _____ Day supply: _____	
<input type="checkbox"/> Fasenra (benralizumab)	<input type="checkbox"/> 10mg/0.5ml PFS <input type="checkbox"/> 30mg/mL PFS <input type="checkbox"/> 30mg/mL autoinjector	<input type="checkbox"/> Inject 10mg/0.5ml subcutaneously every 4 weeks for 3 doses, followed by once every 8 weeks thereafter <input type="checkbox"/> Inject 30mg/ml subcutaneously every 4 weeks for 3 doses, followed by once every 8 weeks thereafter <input type="checkbox"/> Other: Admin _____  <b>Eosinophilic Granulomatosis w/Polyangiitis (EFPA)</b> <input type="checkbox"/> Inject 30mg subcutaneously every 8 weeks  <span style="color: red;">Note: PFS is administered by healthcare provider. Autoinjector can be self-administered or administered by caregiver if patient is 12yrs of age &amp; weighs more than 35kg.</span>	Qty _____ Day supply: _____	
<input type="checkbox"/> Tezspire (tezepelumab)	<input type="checkbox"/> 210mg/1.91ml (110mg/ml) PFS  <input type="checkbox"/> 210mg/1.91ml (110mg/ml) PF pen	Inject 210mg subcutaneously every 4 weeks	Qty _____ Day supply: _____	
<input type="checkbox"/> Nucala (mepolizumab)	<input type="checkbox"/> 100mg vial  <input type="checkbox"/> 100mg/mL autoinjector  <input type="checkbox"/> 100mg/mL PFS <input type="checkbox"/> 40mg/0.4ml PFS	<input type="checkbox"/> (12 years and older): Inject 100mg administered subcutaneously once every 4 weeks  <input type="checkbox"/> Severe asthma (6 to 11 years): Inject 40mg subcutaneously once every 4 weeks  <input type="checkbox"/> Inject 300mg as 3 separate 100mg subcutaneous injections once every 4 weeks  <hr/> <input type="checkbox"/> No supplies requested ( <b>supplies will be sent with shipment unless indicated</b> )	Qty _____ Day supply: _____	

Supplies to be sent:

- 10ml vial sterile water for injection (1 per vial shipped)
- Alcohol swabs
- 3ml syringe, 21G x 1" safety glide needle for reconstitution
- 1ml syringe, 27G x ½" safety glide needle for subcutaneous injection

**INJECTION TRAINING**

Patient has received pen & injection training  Physician's office to provide injection training  Pharmacy to coordinate injection training

**PRESCRIBING PRACTITIONER SIGNATURE**

**Prescribing Practitioner:** The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing this form and utilizing our services, you are also authorizing Medford Chemists Inc. to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

**DAW Brand Medically Necessary**

**May substitute/ Substitution Permissible**

Prescribing Practitioner

Date

**CONFIDENTIALITY NOTICE**

This communication, including any attachments, may contain confidential, proprietary, or legally privileged information intended solely for the use of the designated recipient. If you are not the intended recipient, you are hereby notified that any review, dissemination, distribution, or duplication of this communication is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete all copies of this document.

